Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome

C. J. Fisher, J. Zimmerman, M. B. Khazaeli, Timothy E Albertson, R. P. Dellinger, Edward A Panacek, G. E. Foulke, C. Dating, C. R. Smith, A. F. LoBuglio

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

HA-1A, a human monoclonal immunoglobulin M antibody that binds specifically to the lipid A domain f endotoxin, was administered to septic patients to evaluate the safety, pharmacokinetics, and immunogenicity of the antibody. Thirty-four patients received a single infusion of either 25 mg, 100 mg, or 250 mg, and were followed clinically for 14 to 21 days after treatment. HA-1A serum levels were measured before infusion and frequently after infusion with a radiometric assay. A one-compartment pharmacokinetic model was fit to the measured serum levels, and accurately described the changes in HA-1A level over time in each dose group (r2 = .99). The mean ± SEM apparent volume of distribution of HA-1A was 48.5 ± 4.5 ml/kg, and the mean serum clearance was 2.8 ± 0.4 ml/kg·h. The mean serum half-life of HA-1A was 15.9 ± 1.5 h. The mean serum level one hour after a 100-mg dose was 33.2 ± 2.4 μg/ml, and the mean concentration 24 h later was 9.1 ± 1.6 μg/ml. The dose administered and presence of Gram-negative bacterial infection did not significantly influence the volume of distribution or serum clearance. No adverse reactions to HA-1A were observed, and no antibodies against HA-1A were detected in any patient. These data indicate that the pharmacokinetics of HA-1A are well described by a one-compartment pharmacokinetic model, and that HA-1A is safe and nonimmunogenic in patients with sepsis.

Original languageEnglish (US)
Pages (from-to)1311-1315
Number of pages5
JournalCritical Care Medicine
Volume18
Issue number12
StatePublished - 1990
Externally publishedYes

Fingerprint

Systemic Inflammatory Response Syndrome
Lipid A
Antibodies
Pharmacokinetics
Serum
Gram-Negative Bacterial Infections
Endotoxins
Immunoglobulin M
Half-Life
Sepsis
Safety

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Fisher, C. J., Zimmerman, J., Khazaeli, M. B., Albertson, T. E., Dellinger, R. P., Panacek, E. A., ... LoBuglio, A. F. (1990). Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. Critical Care Medicine, 18(12), 1311-1315.

Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. / Fisher, C. J.; Zimmerman, J.; Khazaeli, M. B.; Albertson, Timothy E; Dellinger, R. P.; Panacek, Edward A; Foulke, G. E.; Dating, C.; Smith, C. R.; LoBuglio, A. F.

In: Critical Care Medicine, Vol. 18, No. 12, 1990, p. 1311-1315.

Research output: Contribution to journalArticle

Fisher, CJ, Zimmerman, J, Khazaeli, MB, Albertson, TE, Dellinger, RP, Panacek, EA, Foulke, GE, Dating, C, Smith, CR & LoBuglio, AF 1990, 'Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome', Critical Care Medicine, vol. 18, no. 12, pp. 1311-1315.
Fisher, C. J. ; Zimmerman, J. ; Khazaeli, M. B. ; Albertson, Timothy E ; Dellinger, R. P. ; Panacek, Edward A ; Foulke, G. E. ; Dating, C. ; Smith, C. R. ; LoBuglio, A. F. / Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. In: Critical Care Medicine. 1990 ; Vol. 18, No. 12. pp. 1311-1315.
@article{4c69a594f1414d5fbc6315a2242af017,
title = "Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome",
abstract = "HA-1A, a human monoclonal immunoglobulin M antibody that binds specifically to the lipid A domain f endotoxin, was administered to septic patients to evaluate the safety, pharmacokinetics, and immunogenicity of the antibody. Thirty-four patients received a single infusion of either 25 mg, 100 mg, or 250 mg, and were followed clinically for 14 to 21 days after treatment. HA-1A serum levels were measured before infusion and frequently after infusion with a radiometric assay. A one-compartment pharmacokinetic model was fit to the measured serum levels, and accurately described the changes in HA-1A level over time in each dose group (r2 = .99). The mean ± SEM apparent volume of distribution of HA-1A was 48.5 ± 4.5 ml/kg, and the mean serum clearance was 2.8 ± 0.4 ml/kg·h. The mean serum half-life of HA-1A was 15.9 ± 1.5 h. The mean serum level one hour after a 100-mg dose was 33.2 ± 2.4 μg/ml, and the mean concentration 24 h later was 9.1 ± 1.6 μg/ml. The dose administered and presence of Gram-negative bacterial infection did not significantly influence the volume of distribution or serum clearance. No adverse reactions to HA-1A were observed, and no antibodies against HA-1A were detected in any patient. These data indicate that the pharmacokinetics of HA-1A are well described by a one-compartment pharmacokinetic model, and that HA-1A is safe and nonimmunogenic in patients with sepsis.",
author = "Fisher, {C. J.} and J. Zimmerman and Khazaeli, {M. B.} and Albertson, {Timothy E} and Dellinger, {R. P.} and Panacek, {Edward A} and Foulke, {G. E.} and C. Dating and Smith, {C. R.} and LoBuglio, {A. F.}",
year = "1990",
language = "English (US)",
volume = "18",
pages = "1311--1315",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome

AU - Fisher, C. J.

AU - Zimmerman, J.

AU - Khazaeli, M. B.

AU - Albertson, Timothy E

AU - Dellinger, R. P.

AU - Panacek, Edward A

AU - Foulke, G. E.

AU - Dating, C.

AU - Smith, C. R.

AU - LoBuglio, A. F.

PY - 1990

Y1 - 1990

N2 - HA-1A, a human monoclonal immunoglobulin M antibody that binds specifically to the lipid A domain f endotoxin, was administered to septic patients to evaluate the safety, pharmacokinetics, and immunogenicity of the antibody. Thirty-four patients received a single infusion of either 25 mg, 100 mg, or 250 mg, and were followed clinically for 14 to 21 days after treatment. HA-1A serum levels were measured before infusion and frequently after infusion with a radiometric assay. A one-compartment pharmacokinetic model was fit to the measured serum levels, and accurately described the changes in HA-1A level over time in each dose group (r2 = .99). The mean ± SEM apparent volume of distribution of HA-1A was 48.5 ± 4.5 ml/kg, and the mean serum clearance was 2.8 ± 0.4 ml/kg·h. The mean serum half-life of HA-1A was 15.9 ± 1.5 h. The mean serum level one hour after a 100-mg dose was 33.2 ± 2.4 μg/ml, and the mean concentration 24 h later was 9.1 ± 1.6 μg/ml. The dose administered and presence of Gram-negative bacterial infection did not significantly influence the volume of distribution or serum clearance. No adverse reactions to HA-1A were observed, and no antibodies against HA-1A were detected in any patient. These data indicate that the pharmacokinetics of HA-1A are well described by a one-compartment pharmacokinetic model, and that HA-1A is safe and nonimmunogenic in patients with sepsis.

AB - HA-1A, a human monoclonal immunoglobulin M antibody that binds specifically to the lipid A domain f endotoxin, was administered to septic patients to evaluate the safety, pharmacokinetics, and immunogenicity of the antibody. Thirty-four patients received a single infusion of either 25 mg, 100 mg, or 250 mg, and were followed clinically for 14 to 21 days after treatment. HA-1A serum levels were measured before infusion and frequently after infusion with a radiometric assay. A one-compartment pharmacokinetic model was fit to the measured serum levels, and accurately described the changes in HA-1A level over time in each dose group (r2 = .99). The mean ± SEM apparent volume of distribution of HA-1A was 48.5 ± 4.5 ml/kg, and the mean serum clearance was 2.8 ± 0.4 ml/kg·h. The mean serum half-life of HA-1A was 15.9 ± 1.5 h. The mean serum level one hour after a 100-mg dose was 33.2 ± 2.4 μg/ml, and the mean concentration 24 h later was 9.1 ± 1.6 μg/ml. The dose administered and presence of Gram-negative bacterial infection did not significantly influence the volume of distribution or serum clearance. No adverse reactions to HA-1A were observed, and no antibodies against HA-1A were detected in any patient. These data indicate that the pharmacokinetics of HA-1A are well described by a one-compartment pharmacokinetic model, and that HA-1A is safe and nonimmunogenic in patients with sepsis.

UR - http://www.scopus.com/inward/record.url?scp=0025678614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025678614&partnerID=8YFLogxK

M3 - Article

C2 - 2245602

AN - SCOPUS:0025678614

VL - 18

SP - 1311

EP - 1315

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 12

ER -